ILMN vs. WAT, MTD, BRKR, BIO, AVTR, RVTY, BIO.B, PHG, STE, and GMAB
Should you be buying Illumina stock or one of its competitors? The main competitors of Illumina include Waters (WAT), Mettler-Toledo International (MTD), Bruker (BRKR), Bio-Rad Laboratories (BIO), Avantor (AVTR), Revvity (RVTY), Bio-Rad Laboratories (BIO.B), Koninklijke Philips (PHG), STERIS (STE), and Genmab A/S (GMAB).
Waters (NYSE:WAT) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.
Waters has a net margin of 21.72% compared to Waters' net margin of -25.78%. Illumina's return on equity of 81.30% beat Waters' return on equity.
In the previous week, Waters had 29 more articles in the media than Illumina. MarketBeat recorded 35 mentions for Waters and 6 mentions for Illumina. Waters' average media sentiment score of 1.03 beat Illumina's score of 0.28 indicating that Illumina is being referred to more favorably in the news media.
Waters currently has a consensus price target of $298.67, indicating a potential downside of 4.06%. Illumina has a consensus price target of $167.70, indicating a potential upside of 37.14%. Given Waters' stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than Waters.
Waters has higher earnings, but lower revenue than Illumina. Illumina is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.
Illumina received 647 more outperform votes than Waters when rated by MarketBeat users. Likewise, 65.73% of users gave Illumina an outperform vote while only 54.58% of users gave Waters an outperform vote.
94.0% of Waters shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 0.8% of Waters shares are owned by company insiders. Comparatively, 0.2% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Waters has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Summary
Waters beats Illumina on 10 of the 18 factors compared between the two stocks.
Get Illumina News Delivered to You Automatically
Sign up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Illumina Competitors List
Related Companies and Tools
